Pub Date : 2025-01-01DOI: 10.1016/j.patol.2024.100788
Angélica Yeyli Asencio Aguedo , Omar Lorenzo Reyes Morales , Ingrid Janina Juárez Chávez
Gestational trophoblastic tumours are neoplasms that derive from trophoblastic tissue; therefore, their occurrence is generally intrauterine. We report the case of a 27-year-old woman with an ovarian tumour that arose during pregnancy. The patient did not have postpartum checkups and came to the clinic after eighteen months, presenting multiple lymphadenopathy predominantly in the cervical region, one of which was biopsied. In the microscopic study, the presence of syncytiotrophoblast-like cells supported the diagnosis of a metastasis of gestational trophoblastic neoplasia. The serum levels of bHCG were found to be elevated. Tomographic and ultrasound images did not show any uterine tumour. Immunohistochemistry allowed us to establish the diagnosis of placental site trophoblastic tumour metastasis.
{"title":"Gestational trophoblastic neoplasia associated with a normal pregnancy with no evidence of uterine primary lesion","authors":"Angélica Yeyli Asencio Aguedo , Omar Lorenzo Reyes Morales , Ingrid Janina Juárez Chávez","doi":"10.1016/j.patol.2024.100788","DOIUrl":"10.1016/j.patol.2024.100788","url":null,"abstract":"<div><div>Gestational trophoblastic tumours are neoplasms that derive from trophoblastic tissue; therefore, their occurrence is generally intrauterine. We report the case of a 27-year-old woman with an ovarian tumour that arose during pregnancy. The patient did not have postpartum checkups and came to the clinic after eighteen months, presenting multiple lymphadenopathy predominantly in the cervical region, one of which was biopsied. In the microscopic study, the presence of syncytiotrophoblast-like cells supported the diagnosis of a metastasis of gestational trophoblastic neoplasia. The serum levels of bHCG were found to be elevated. Tomographic and ultrasound images did not show any uterine tumour. Immunohistochemistry allowed us to establish the diagnosis of placental site trophoblastic tumour metastasis.</div></div>","PeriodicalId":39194,"journal":{"name":"Revista Espanola de Patologia","volume":"58 1","pages":"Article 100788"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142967232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.patol.2024.100799
Luis Manuel Fernández Fernández , María de la Paz González Gutiérrez , Miriam Rubiera , Mario Luis Berrios Hernández , Clara González Rodríguez , Miguel Ariza Prota , José Fernando Pérez Fontán , Karen Villar Zarra , Jesús Nieves-Alonso , José Javier Gómez-Román , María Dolores Lozano , Miguel Ángel Pérez-Machado , Enrique Colado Varela , Héctor-Enrique Torres-Rivas
Introduction
Microscopic assessment is essential in the study of mediastinal lymph nodes. Obtaining cytological samples through Endobronchial Ultrasound TransBronchial Needle Aspiration (EBUS-TBNA) has long been considered the gold standard procedure. The implementation of the World Health Organization (WHO) Reporting System for Lymph Node Cytopathology, along with the advancement of the CryoEBUS lymph node technique, has enhanced and refined diagnostic accuracy in this field.
Materials and method
During a two-year period, cases involving the parallel performance of EBUS-TBNA and CryoEBUS specimen collection were quantified. The implementation of the WHO Reporting System allowed for the comparison of diagnostic yield between cytological and CryoEBUS tissue samples.
Results
A total of 178 EBUS-TBNA and CryoEBUS procedures were conducted, with a mean patient age of 63 years and a male predominance of 72.5%. Lymph node station 7 was the most sampled site, accounting for 38.76% of cases. Category V – malignant was the most common cytological diagnosis, representing 50% of cases, while 46.62% of CryoEBUS samples were malignant. The Pearson correlation coefficient between the two methods was calculated at 0.99.
Conclusions
The combined implementation of the WHO Reporting System for Lymph Node Cytopathology and the simultaneous use of CryoEBUS resulted in enhanced performance and diagnostic accuracy, reducing non-diagnostic samples to less than 3%.
{"title":"EBUS-TBNA and CryoEBUS of the mediastinal lymph node. One hundred seventy-eight cases. Validation of the WHO Reporting System for Lymph Node Cytopathology. Proposed CryoEBUS diagnostic flow chart and indications. The view of the interventional pathologist","authors":"Luis Manuel Fernández Fernández , María de la Paz González Gutiérrez , Miriam Rubiera , Mario Luis Berrios Hernández , Clara González Rodríguez , Miguel Ariza Prota , José Fernando Pérez Fontán , Karen Villar Zarra , Jesús Nieves-Alonso , José Javier Gómez-Román , María Dolores Lozano , Miguel Ángel Pérez-Machado , Enrique Colado Varela , Héctor-Enrique Torres-Rivas","doi":"10.1016/j.patol.2024.100799","DOIUrl":"10.1016/j.patol.2024.100799","url":null,"abstract":"<div><h3>Introduction</h3><div>Microscopic assessment is essential in the study of mediastinal lymph nodes. Obtaining cytological samples through Endobronchial Ultrasound TransBronchial Needle Aspiration (EBUS-TBNA) has long been considered the gold standard procedure. The implementation of the World Health Organization (WHO) Reporting System for Lymph Node Cytopathology, along with the advancement of the CryoEBUS lymph node technique, has enhanced and refined diagnostic accuracy in this field.</div></div><div><h3>Materials and method</h3><div>During a two-year period, cases involving the parallel performance of EBUS-TBNA and CryoEBUS specimen collection were quantified. The implementation of the WHO Reporting System allowed for the comparison of diagnostic yield between cytological and CryoEBUS tissue samples.</div></div><div><h3>Results</h3><div>A total of 178 EBUS-TBNA and CryoEBUS procedures were conducted, with a mean patient age of 63 years and a male predominance of 72.5%. Lymph node station 7 was the most sampled site, accounting for 38.76% of cases. Category V – malignant was the most common cytological diagnosis, representing 50% of cases, while 46.62% of CryoEBUS samples were malignant. The Pearson correlation coefficient between the two methods was calculated at 0.99.</div></div><div><h3>Conclusions</h3><div>The combined implementation of the WHO Reporting System for Lymph Node Cytopathology and the simultaneous use of CryoEBUS resulted in enhanced performance and diagnostic accuracy, reducing non-diagnostic samples to less than 3%.</div></div>","PeriodicalId":39194,"journal":{"name":"Revista Espanola de Patologia","volume":"58 1","pages":"Article 100799"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143013595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Early-onset Myopathy, Areflexia, Respiratory Distress and Dysphagia (EMARDD) is a congenital neuromuscular disease with a progressive muscle weakness, respiratory failure, joint contractures, and scoliosis without any symptoms of functional brain anomalies caused by variants in the MEGF10 gene. Here, we report the clinical phenotype and genetic features of a Moroccan patient who carries a novel variant associated with EMARDD on the MEGF10 gene. The Whole Exome Sequencing analysis conducted on a 11 year old boy with respiratory and swallowing difficulties revealed the presence of the novel variant c.978T>A (p.Cys326Ter) on exon 9 of the MEGF10 gene; this variant is thought to be associated with EMARDD. Our study reports the first nonsense pathogenic de novo variant in MEGF10 associated with EMARDD worldwide, identified in a Moroccan patient.
早发性肌病、反射、呼吸窘迫和吞咽困难（EMARDD）是一种先天性神经肌肉疾病，表现为进行性肌肉无力、呼吸衰竭、关节挛缩和脊柱侧凸，没有任何由MEGF10基因变异引起的功能性脑异常症状。在这里，我们报告了一名摩洛哥患者的临床表型和遗传特征，该患者在MEGF10基因上携带一种与EMARDD相关的新变异。对一名患有呼吸和吞咽困难的11岁男孩进行的全外显子组测序分析显示，在MEGF10基因的第9外显子上存在新的变异c.978T b> a (p.Cys326Ter)；这种变异被认为与EMARDD有关。我们的研究报告了全球首例与EMARDD相关的MEGF10无义致病性从头变异，发现于一名摩洛哥患者。
{"title":"Identification of a de-novo variant of the MEGF10 gene associated with EMARDD","authors":"Loubna Darfallah , Najat Sifeddine , Ghita Amalou , Chaimaa Ait El Cadi , Hamid Lakhiari , Abdelhamid Barakat , Hassan Rouba","doi":"10.1016/j.patol.2024.100795","DOIUrl":"10.1016/j.patol.2024.100795","url":null,"abstract":"<div><div>Early-onset Myopathy, Areflexia, Respiratory Distress and Dysphagia (EMARDD) is a congenital neuromuscular disease with a progressive muscle weakness, respiratory failure, joint contractures, and scoliosis without any symptoms of functional brain anomalies caused by variants in the <em>MEGF10</em> gene. Here, we report the clinical phenotype and genetic features of a Moroccan patient who carries a novel variant associated with EMARDD on the <em>MEGF10</em> gene. The Whole Exome Sequencing analysis conducted on a 11 year old boy with respiratory and swallowing difficulties revealed the presence of the novel variant c.978T>A (p.Cys326Ter) on exon 9 of the <em>MEGF10</em> gene; this variant is thought to be associated with EMARDD. Our study reports the first nonsense pathogenic de novo variant in <em>MEGF10</em> associated with EMARDD worldwide, identified in a Moroccan patient.</div></div>","PeriodicalId":39194,"journal":{"name":"Revista Espanola de Patologia","volume":"58 1","pages":"Article 100795"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143013597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Malignant adenomyoepithelioma of the breast is a rare and challenging tumor in terms of diagnosis and treatment. It is exceptional to find this condition in a patient who has had breast cancer treated with breast-conserving surgery and radiotherapy. We present the case of a 46-year-old female patient with a history of invasive lobular carcinoma of the breast, who presented one year later with a malignant adenomyoepithelioma in the same breast, which recurred three times, despite undergoing various surgical treatments and even adjuvant chemotherapy regimen. The limited evidence and lack of consensus in the management of this type of tumor highlight the importance of a multidisciplinary approach. Upon reviewing the literature, we observed extensive heterogeneity in treatments and the lack of a gold standard. We believe that surgery is the cornerstone of treatment, and that both chemotherapy and radiotherapy may have a benefit that is still unknown.
{"title":"Malignant adenomyoepithelioma after breast cancer with multiple local recurrences","authors":"Gelblung Brian , Quenardelle Mariano , Risau Estefanía , Spengler Eunice , Beccar Varela Eduardo","doi":"10.1016/j.patol.2024.100792","DOIUrl":"10.1016/j.patol.2024.100792","url":null,"abstract":"<div><div>Malignant adenomyoepithelioma of the breast is a rare and challenging tumor in terms of diagnosis and treatment. It is exceptional to find this condition in a patient who has had breast cancer treated with breast-conserving surgery and radiotherapy. We present the case of a 46-year-old female patient with a history of invasive lobular carcinoma of the breast, who presented one year later with a malignant adenomyoepithelioma in the same breast, which recurred three times, despite undergoing various surgical treatments and even adjuvant chemotherapy regimen. The limited evidence and lack of consensus in the management of this type of tumor highlight the importance of a multidisciplinary approach. Upon reviewing the literature, we observed extensive heterogeneity in treatments and the lack of a gold standard. We believe that surgery is the cornerstone of treatment, and that both chemotherapy and radiotherapy may have a benefit that is still unknown.</div></div>","PeriodicalId":39194,"journal":{"name":"Revista Espanola de Patologia","volume":"58 1","pages":"Article 100792"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143068560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Intranodal palisaded myofibroblastoma (IPM) arising in the axilla is an extremely rare, benign mesenchymal tumour. It is believed to originate from myofibroblast or smooth muscle cells and exhibits specific histopathological features. While there have been occasional cases of recurrence, no malignant transformation has been observed. We describe the case of a 35-year-old male presenting with an axillary mass. Histopathology revealed a tumour with a pseudo-capsule that contains compressed lymphoid tissue with spindle cells arranged in a palisade-like pattern and extravasation of red blood cells within the spindle cells. Additionally, amianthoid fibres and fuchsinophilic bodies are present. Immunohistochemical analysis typically was positive for SMA and cyclin D1, with a low proliferative index (Ki67 of <1%). The diagnosis was intranodal palisading myofibroblastoma. Only two cases of IPM in the axilla have been previously reported. Pathologists should keep this rare entity with characteristic histopathological findings in mind when reporting such tumours at an unusual site.
{"title":"Axillary intranodal palisaded myofibroblastoma, a rare tumour at an unusual site, with literature review","authors":"Durre Aden, Minnat Sharma, Sufian Zaheer, Sunil Ranga","doi":"10.1016/j.patol.2024.100791","DOIUrl":"10.1016/j.patol.2024.100791","url":null,"abstract":"<div><div>Intranodal palisaded myofibroblastoma (IPM) arising in the axilla is an extremely rare, benign mesenchymal tumour. It is believed to originate from myofibroblast or smooth muscle cells and exhibits specific histopathological features. While there have been occasional cases of recurrence, no malignant transformation has been observed. We describe the case of a 35-year-old male presenting with an axillary mass. Histopathology revealed a tumour with a pseudo-capsule that contains compressed lymphoid tissue with spindle cells arranged in a palisade-like pattern and extravasation of red blood cells within the spindle cells. Additionally, amianthoid fibres and fuchsinophilic bodies are present. Immunohistochemical analysis typically was positive for SMA and cyclin D1, with a low proliferative index (Ki67 of <1%). The diagnosis was intranodal palisading myofibroblastoma. Only two cases of IPM in the axilla have been previously reported. Pathologists should keep this rare entity with characteristic histopathological findings in mind when reporting such tumours at an unusual site.</div></div>","PeriodicalId":39194,"journal":{"name":"Revista Espanola de Patologia","volume":"58 1","pages":"Article 100791"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143075719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.patol.2024.100793
Sana Ahuja , Aanchal Bhayana , Sufian Zaheer
Background
The diagnosis of breast cancer necessitates a multifaceted approach integrating cytopathological and radiological assessments. The International Academy of Cytology (IAC) Yokohama system and Breast Imaging Reporting and Data System (BI-RADS) are fundamental frameworks in this context. This study aims to evaluate the diagnostic potential of a combined Yokohama-BI-RADS scoring system for breast lesions.
Materials and methods
A retrospective analysis was conducted on fine needle aspirates from January to June 2023. The cases were classified using the IAC Yokohama system and sono-mammography BI-RADS score. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and diagnostic accuracy were calculated using histopathological diagnoses as the reference standard. Optimal cut-off scores for the combined scoring system were determined.
Results
Among 52 patients, cytological diagnoses encompassed non-diagnostic, benign, atypical, suspicious of malignancy, and malignant categories. BI-RADS scores ranged from 1 to 5. The combined Yokohama-BI-RADS score exhibited superior diagnostic accuracy (AUC: 0.986) compared to individual systems.
Conclusion
The combined Yokohama-BI-RADS scoring system represents a promising advancement in breast lesion evaluation, providing enhanced diagnostic precision by integrating cytopathological and radiological data. This approach has the potential to optimize clinical decision-making and contribute to improved patient outcomes in breast cancer management.
{"title":"Maximizing diagnostic precision: Evaluating the combined Yokohama and BI-RADS scoring system for breast lesions","authors":"Sana Ahuja , Aanchal Bhayana , Sufian Zaheer","doi":"10.1016/j.patol.2024.100793","DOIUrl":"10.1016/j.patol.2024.100793","url":null,"abstract":"<div><h3>Background</h3><div>The diagnosis of breast cancer necessitates a multifaceted approach integrating cytopathological and radiological assessments. The International Academy of Cytology (IAC) Yokohama system and Breast Imaging Reporting and Data System (BI-RADS) are fundamental frameworks in this context. This study aims to evaluate the diagnostic potential of a combined Yokohama-BI-RADS scoring system for breast lesions.</div></div><div><h3>Materials and methods</h3><div>A retrospective analysis was conducted on fine needle aspirates from January to June 2023. The cases were classified using the IAC Yokohama system and sono-mammography BI-RADS score. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and diagnostic accuracy were calculated using histopathological diagnoses as the reference standard. Optimal cut-off scores for the combined scoring system were determined.</div></div><div><h3>Results</h3><div>Among 52 patients, cytological diagnoses encompassed non-diagnostic, benign, atypical, suspicious of malignancy, and malignant categories. BI-RADS scores ranged from 1 to 5. The combined Yokohama-BI-RADS score exhibited superior diagnostic accuracy (AUC: 0.986) compared to individual systems.</div></div><div><h3>Conclusion</h3><div>The combined Yokohama-BI-RADS scoring system represents a promising advancement in breast lesion evaluation, providing enhanced diagnostic precision by integrating cytopathological and radiological data. This approach has the potential to optimize clinical decision-making and contribute to improved patient outcomes in breast cancer management.</div></div>","PeriodicalId":39194,"journal":{"name":"Revista Espanola de Patologia","volume":"58 1","pages":"Article 100793"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143013599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.patol.2024.100790
Grecia Gonzales-Céspedes, Samuel Navarro
High-risk neuroblastoma continues to show a very high mortality, with a 5-year survival rate of 50%. While MYCN amplification is the main genetic alteration associated with high-risk tumours, other molecular mechanisms, such as alterations in ATRX and TERT, remain poorly understood.
ATRX and TERT biomarkers, which are associated with a more aggressive neuroblastoma pattern, should be considered for accurate prognostic stratification.
We highlight the promising results of the clinical trial involving the combination of adavosertib and irinotecan, which encourages further clinical trials with adavosertib targeting NB with ATRX mutations. Preclinical results with BET inhibitors (OTX015 and AZD5153) and with 6-thio-2′-deoxyguanosine, targeting NB with TERT mutations, are promising. Both represent future therapeutic targets, emphasizing the need to prioritize research using these models.
{"title":"High-risk neuroblastoma: ATRX and TERT as prognostic markers and therapeutic targets. Review and update on the topic","authors":"Grecia Gonzales-Céspedes, Samuel Navarro","doi":"10.1016/j.patol.2024.100790","DOIUrl":"10.1016/j.patol.2024.100790","url":null,"abstract":"<div><div>High-risk neuroblastoma continues to show a very high mortality, with a 5-year survival rate of 50%. While MYCN amplification is the main genetic alteration associated with high-risk tumours, other molecular mechanisms, such as alterations in ATRX and TERT, remain poorly understood.</div><div>ATRX and TERT biomarkers, which are associated with a more aggressive neuroblastoma pattern, should be considered for accurate prognostic stratification.</div><div>We highlight the promising results of the clinical trial involving the combination of adavosertib and irinotecan, which encourages further clinical trials with adavosertib targeting NB with ATRX mutations. Preclinical results with BET inhibitors (OTX015 and AZD5153) and with 6-thio-2′-deoxyguanosine, targeting NB with TERT mutations, are promising. Both represent future therapeutic targets, emphasizing the need to prioritize research using these models.</div></div>","PeriodicalId":39194,"journal":{"name":"Revista Espanola de Patologia","volume":"58 1","pages":"Article 100790"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142967234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.patol.2024.100789
Hinpetch Daungsupawong , Viroj Wiwanitkit
{"title":"ChatGPT is an above-average student at the Faculty of Medicine and the development of teaching materials: Comment","authors":"Hinpetch Daungsupawong , Viroj Wiwanitkit","doi":"10.1016/j.patol.2024.100789","DOIUrl":"10.1016/j.patol.2024.100789","url":null,"abstract":"","PeriodicalId":39194,"journal":{"name":"Revista Espanola de Patologia","volume":"58 1","pages":"Article 100789"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143156318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-01DOI: 10.1016/j.patol.2024.04.005
Antonio Martínez Lorente , Esther Rosello Sastre , María Jesús Fernández Aceñero , Lara Zaragoza Macián , Javier Azúa Romeo , Clara Alfaro-Cervelló , Samuel Navarro , Eugenia García Fernández , Jordi Temprana-Salvador , Mar Iglesias Coma , Francesc Olivares Vegas , Maite Fernández Figueras , Sonsoles Aso Manso , José Javier Aguirre Anda , José Santos Salas Valién , Ramiro Álvarez Alegret , Javier Hernández Losa , Cristina Jou Muñoz , Carme Dinarès Fernández , Marina Urbano Carrillo , Francesc Tresserra Casas
The working group set up by the SEAP-IAP addresses in this Part II some general considerations and five particular considerations to be taken into account when a biological sample of human origin, coming from our archives, acquires a different destination from the usual one, in this case for research. From this moment on, we must follow mandatory legal and ethical rules, and the different recitals provide us with guidelines to ensure good practice, both for biological material and its associated data. The traditional task of custody given to the Pathological Anatomy is approached, as always, from the point of view of responsibility and, in this article, adjusted to its time.
SEAP-IAP 设立的工作组在本文件的第 II 部分中讨论了当来自我们档案馆的人类生物样 本的目的地不同于通常的目的地（即用于研究）时应考虑的一些一般因素和五个特殊因素。从这一刻起，我们必须遵守强制性的法律和伦理规则，不同的条文为我们提供了指 导，以确保生物材料及其相关数据的良好做法。我们一如既往地从责任的角度出发，对病理解剖学的传统保管任务进行了探讨，并在本文中进行了相应的调整。
{"title":"Recomendaciones de la SEAP-IAP para la recolección, el almacenamiento y el uso de materiales biológicos de origen humano y los datos relacionados, destinados a la investigación. Consideración genérica de biobanco y revisión ético-legal (Parte II)","authors":"Antonio Martínez Lorente , Esther Rosello Sastre , María Jesús Fernández Aceñero , Lara Zaragoza Macián , Javier Azúa Romeo , Clara Alfaro-Cervelló , Samuel Navarro , Eugenia García Fernández , Jordi Temprana-Salvador , Mar Iglesias Coma , Francesc Olivares Vegas , Maite Fernández Figueras , Sonsoles Aso Manso , José Javier Aguirre Anda , José Santos Salas Valién , Ramiro Álvarez Alegret , Javier Hernández Losa , Cristina Jou Muñoz , Carme Dinarès Fernández , Marina Urbano Carrillo , Francesc Tresserra Casas","doi":"10.1016/j.patol.2024.04.005","DOIUrl":"10.1016/j.patol.2024.04.005","url":null,"abstract":"<div><div>The working group set up by the SEAP-IAP addresses in this <em>Part II</em> some general considerations and five particular considerations to be taken into account when a biological sample of human origin, coming from our archives, acquires a different destination from the usual one, in this case for research. From this moment on, we must follow mandatory legal and ethical rules, and the different recitals provide us with guidelines to ensure good practice, both for biological material and its associated data. The traditional task of custody given to the Pathological Anatomy is approached, as always, from the point of view of responsibility and, in this article, adjusted to its time.</div></div>","PeriodicalId":39194,"journal":{"name":"Revista Espanola de Patologia","volume":"57 4","pages":"Pages 250-257"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141843770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
B-cell lymphoma-2 (BCL-2) is an anti-apoptotic protein that may play a role in disordered proliferative endometrium (DPE) and endometrial hyperplasia (EH). Several studies have investigated BCL-2 expression in normal, hyperplastic endometrium and endometrial adenocarcinoma, with conflicting results. Therefore, the present study aimed to compare the expression of BCL-2 in disordered proliferative endometrium and simple EH.
Methods
In this cross-sectional study, 63 DPE and 67 SEH samples from patients referred to Mostafa Khomeini Hospital between 2017 and 2022 were immunohistochemically stained by BCL-2 antibody. BCL-2 expression in each sample was reported as negative, weak positive, and strong positive. The findings were analyzed using SPSS version 16 software.
Results
Negative, weakly positive, and strongly positive BCL-2 expression was observed in 55.6%, 38.1%, and 6.3% of DPE samples, and 61.2%, 31.3%, and 7.5% of SEH samples, respectively, which does not show a statistically significant difference (p = 0.718). There was no relationship between the age of patients and BCL-2 expression in any of the two groups of DPE and SEH (p = 0.378 and p = 0.178, respectively).
Conclusion
BCL-2 expression is observed with a relatively similar frequency in DPE and SEH samples, and it is probably under the control of oestrogen hormone as the main factor involved in the pathogenesis of these lesions.
{"title":"Comparison of B-cell lymphoma 2 (BCL-2) expression in disordered proliferative endometrium and simple endometrial hyperplasia","authors":"Zahra Ghorbanniadelavar , Mohammadreza Jalali Nadoushan , Masood Soltanipur","doi":"10.1016/j.patol.2024.05.005","DOIUrl":"10.1016/j.patol.2024.05.005","url":null,"abstract":"<div><h3>Background and objective</h3><div>B-cell lymphoma-2 (BCL-2) is an anti-apoptotic protein that may play a role in disordered proliferative endometrium (DPE) and endometrial hyperplasia (EH). Several studies have investigated BCL-2 expression in normal, hyperplastic endometrium and endometrial adenocarcinoma, with conflicting results. Therefore, the present study aimed to compare the expression of BCL-2 in disordered proliferative endometrium and simple EH.</div></div><div><h3>Methods</h3><div>In this cross-sectional study, 63 DPE and 67 SEH samples from patients referred to Mostafa Khomeini Hospital between 2017 and 2022 were immunohistochemically stained by BCL-2 antibody. BCL-2 expression in each sample was reported as negative, weak positive, and strong positive. The findings were analyzed using SPSS version 16 software.</div></div><div><h3>Results</h3><div>Negative, weakly positive, and strongly positive BCL-2 expression was observed in 55.6%, 38.1%, and 6.3% of DPE samples, and 61.2%, 31.3%, and 7.5% of SEH samples, respectively, which does not show a statistically significant difference (<em>p</em> <!-->=<!--> <!-->0.718). There was no relationship between the age of patients and BCL-2 expression in any of the two groups of DPE and SEH (<em>p</em> <!-->=<!--> <!-->0.378 and <em>p</em> <!-->=<!--> <!-->0.178, respectively).</div></div><div><h3>Conclusion</h3><div>BCL-2 expression is observed with a relatively similar frequency in DPE and SEH samples, and it is probably under the control of oestrogen hormone as the main factor involved in the pathogenesis of these lesions.</div></div>","PeriodicalId":39194,"journal":{"name":"Revista Espanola de Patologia","volume":"57 4","pages":"Pages 265-272"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141713264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号